Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

• Published in: Journal of clinical oncology Vol. 30; no. 18; pp. 2183 - 2189
• Main Authors: Younes, Anas, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Ramchandren, Radhakrishnan, Bartlett, Nancy L., Cheson, Bruce D., de Vos, Sven, Forero-Torres, Andres, Moskowitz, Craig H., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Kennedy, Dana A., Sievers, Eric L., Chen, Robert
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Society of Clinical Oncology 20.06.2012
• Subjects: Adolescent; Adult; Aged; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Disease-Free Survival; Female; Hematologic and hematopoietic diseases; Hodgkin Disease - drug therapy; Humans; Immunoconjugates - adverse effects; Immunoconjugates - therapeutic use; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; ORIGINAL REPORTS; Recurrence; Tumors; Young Adult; Human; Relapse; Treatment resistance; Cancerology; Treatment; Lymphoproliferative syndrome; Phase II trial; Hodgkin disease; Malignant hemopathy; Lymphoma; Cancer
• ISSN: 0732-183X; 1527-7755; 1527-7755
• DOI: 10.1200/JCO.2011.38.0410

Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapsed or refr...